Figure 2. Changes in serum hepatitis B virus markers from baseline to week 52. Patients in the groups labeled "adefovir" or "telbivudine" received 52 weeks of adefovir (group B) or telbivudine (group A) treatment, respectively. Patients in the group labeled "adefovir/telbivudine" received 24 weeks of adefovir followed by 28 weeks of telbivudine (group C). Top. Mean serum HBV DNA levels. Bottom. Proportions of patients with HBeAg seroconversion.